NCT04204473View on ClinicalTrials.gov

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

May 7, 2020

Primary Completion Date

March 3, 2023

Study Completion Date

May 18, 2023

Conditions
NSCLC
Interventions
DRUG

TY-9591(10mg,40mg) qd. po

Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)

Trial Locations (1)

201203

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

TYK Medicines, Inc

INDUSTRY

NCT04204473 - A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation | Biotech Hunter | Biotech Hunter